Breaking News Instant updates and real-time market news.

AXON

Axovant Sciences

$14.12

0.67 (4.98%)

, LLY

Eli Lilly

$68.00

-7.99 (-10.51%)

09:06
11/25/16
11/25
09:06
11/25/16
09:06

Lilly trial failure has little to do with Axovant Sciences, says Baird

Baird analyst Brian Skorney said Eli Lilly's (LLY) solanezumab drug trial failure has little to do with Axovant Sciences (AXON) drug trial for Alzheimer's. The analyst said Lilly's failure is a reminder of the difficulty of the disease, but the two company's drugs are very different and meant to have very different effects. Skorney reiterated his Outperform rating and $29 price target on Axovant shares.

AXON

Axovant Sciences

$14.12

0.67 (4.98%)

LLY

Eli Lilly

$68.00

-7.99 (-10.51%)

  • 29

    Nov

  • 04

    Dec

AXON Axovant Sciences
$14.12

0.67 (4.98%)

09/22/16
HCWC
09/22/16
NO CHANGE
Target $35
HCWC
Buy
No read-through from idalopirdine to Axovant RVT-101, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein notes that Lundbeck announced that its idalopirdine missed its primary and secondary endpoints in the STARSHINE Phase 3 study in mild/moderate Alzheimer's disease. However, Fein says that idalopirdine miss does not shake his confidence in Axovant's RVT-101 as he believes Lundbeck may have simply not been able to dose idalopirdine high enough in the Phase 3 program, which minimizes read-through to Axovant's MINDSET Phase 3 study. He continues to believe that Axovant's own experimental Alzheimer's therapy is well positioned for a win. Fein reiterates a Buy rating and $35 price target on Axovant's shares. In afternoon trading, Axovant's stock has dropped almost 12% to $15.31 per share.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $32
PIPR
Overweight
Axovant Sciences selloff provides entry point, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes yesterday's selloff in shares of Axovant Sciences provides an entry point into the name. Lundbeck's announcement that its first Phase III data with idalopirdine in Alzheimer's missed the primary endpoint does not have predictive value for the Axovant's ongoing RVT-101 Phase III study, Duncan tells investors in a research note. The analyst sees "several key differences" between the two candidates and Phase III programs. He believes RVT-101 is the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. Duncan reiterates an Overweight rating on Axovant with a $32 price target.
11/23/16
BARD
11/23/16
NO CHANGE
BARD
Axovant Sciences outlook unchanged on Lilly's solanezumab failure, says Baird
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Axovant not impacted by Lilly's solanezumab failure, says JMP Securities
JMP Securities analyst Jason Butler said Axovant Sciences (AXON) is not impacted by Eli Lilly's (LLY) solanezumab. The analyst said solanezumab has a very different mechanism of action, and unlike solanezumab, Axovant's has already prospectively demonstrated statistically significant improvements in cognition and function in a pivotal trial. Butler recommends buying Axovant on weakness and reiterates his Outperform rating and $36 price target.
LLY Eli Lilly
$68.00

-7.99 (-10.51%)

11/23/16
BMOC
11/23/16
DOWNGRADE
BMOC
Market Perform
Eli Lilly downgraded to Market Perform from Outperform at BMO Capital
11/25/16
RHCO
11/25/16
NO CHANGE
Target $101
RHCO
Buy
Eli Lilly price target lowered to $101 from $107 at SunTrust
SunTrust analyst John Boris removed solanezumab, which he had viewed as a "high risk/high reward" asset, from his model after the company reported a Phase 3 study showed that the drug failed to slow loss of cognitive ability in patients with mild Alzheimer's disease. Boris cut his price target on Lilly shares to $101 from $107, but recommends taking advantage of weakness in the shares, on which he keeps a Buy rating.
11/25/16
UBSW
11/25/16
NO CHANGE
Target $70
UBSW
Neutral
Eli Lilly price target lowered to $70 from $82 at UBS
UBS analyst Marc Goodman lowered his price target on Eli Lilly to $70 from $82 following the halt of its solanezumab drug trial for Alzheimer's. The analyst removed his sales estimates for solanezumab and said that without its contribution he is less optimistic for top-line growth. Goodman recommends investors stay on the sidelines and reiterated his Neutral rating on Eli Lilly shares.

TODAY'S FREE FLY STORIES

VFC

VF Corp.

$57.14

1.35 (2.42%)

15:36
12/05/16
12/05
15:36
12/05/16
15:36
Technical Analysis
VF Corp. rises, rounding bottom pattern »

The stock is up over 2.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYGN

Myriad Genetics

$16.66

0.02 (0.12%)

15:30
12/05/16
12/05
15:30
12/05/16
15:30
Options
Vote of confidence in Myriad Genetics will result in big open interest increase »

Vote of confidence in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SMTC

Semtech

$30.30

1.2 (4.12%)

15:25
12/05/16
12/05
15:25
12/05/16
15:25
Conference/Events
Semtech management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

MMI

Marcus & Millichap

$27.78

0.49 (1.80%)

15:25
12/05/16
12/05
15:25
12/05/16
15:25
Hot Stocks
Marcus & Millichap's IPA unit closes sale of Isle at Arrowhead Ranch for $42M »

Marcus & Millichap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

15:25
12/05/16
12/05
15:25
12/05/16
15:25
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

RDI

Reading International

$15.76

-0.17 (-1.07%)

15:24
12/05/16
12/05
15:24
12/05/16
15:24
Conference/Events
Reading International management to meet with B. Riley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

ON

ON Semiconductor

$11.12

0.15 (1.37%)

15:22
12/05/16
12/05
15:22
12/05/16
15:22
Conference/Events
ON Semiconductor management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SUP

Superior Industries

$25.43

0.725 (2.94%)

15:20
12/05/16
12/05
15:20
12/05/16
15:20
Conference/Events
Superior Industries management to meet with B. Riley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 10

    Jan

VFC

VF Corp.

$57.11

1.315 (2.36%)

15:20
12/05/16
12/05
15:20
12/05/16
15:20
Options
5X average daily option volume in VFC driven by a three-way spread »

5X average daily option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIQ

Alliance HealthCare

15:16
12/05/16
12/05
15:16
12/05/16
15:16
Hot Stocks
Alliance HealthCare Radiology forms partnership with Sodexo Healthcare »

Alliance HealthCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
12/05/16
12/05
15:16
12/05/16
15:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:16
12/05/16
12/05
15:16
12/05/16
15:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavier than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STO

Statoil

$17.74

0.025 (0.14%)

, BP

BP

$35.59

0.11 (0.31%)

15:15
12/05/16
12/05
15:15
12/05/16
15:15
Periodicals
Statoil, BP, Total group awarded first block in Salina auction, Reuters says »

Mexico has awarded a…

STO

Statoil

$17.74

0.025 (0.14%)

BP

BP

$35.59

0.11 (0.31%)

TOT

Total

$48.33

0.55 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCO

Clear Channel Outdoor

$5.55

-0.1 (-1.77%)

15:10
12/05/16
12/05
15:10
12/05/16
15:10
Hot Stocks
Clear Channel Airports awarded 10-year contract extension by MNAA »

Clear Channel Airports, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.78

0.1735 (0.45%)

, INTC

Intel

$34.16

0.4 (1.18%)

15:06
12/05/16
12/05
15:06
12/05/16
15:06
Hot Stocks
AT&T launches first 5G business customer trial with Intel and Ericsson »

AT&T (T) said it has…

T

AT&T

$38.78

0.1735 (0.45%)

INTC

Intel

$34.16

0.4 (1.18%)

ERIC

Ericsson

$5.16

0.04 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

  • 29

    Mar

LLL

L-3 Communications

$157.70

0.47 (0.30%)

15:03
12/05/16
12/05
15:03
12/05/16
15:03
Conference/Events
L-3 Communications to host investor meeting with conference call hookup »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PARR

Par Pacific

$15.19

0.2 (1.33%)

14:55
12/05/16
12/05
14:55
12/05/16
14:55
Hot Stocks
Whitebox Advisors cuts Par Pacific stake to 16.4% from 18.2% »

Whitebox Advisors, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:55
12/05/16
12/05
14:55
12/05/16
14:55
Conference/Events
U.S. Vice President Biden speaks on financial regulation »

Vice President Biden,…

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

14:55
12/05/16
12/05
14:55
12/05/16
14:55
Conference/Events
Global Blood Therapeutics to hold a webcast »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

NEWM

New Media

$15.93

-0.06 (-0.38%)

, DTSI

DTS, Inc.

14:55
12/05/16
12/05
14:55
12/05/16
14:55
Hot Stocks
New Media to replace DTS, Inc. in S&P 600 as of 12/5 close »

S&P SmallCap 600…

NEWM

New Media

$15.93

-0.06 (-0.38%)

DTSI

DTS, Inc.

TSRA

Tessera

$39.30

0.2 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBHC

National Bank

$29.99

0.835 (2.86%)

, ININ

Interactive Intelligence

14:55
12/05/16
12/05
14:55
12/05/16
14:55
Hot Stocks
National Bank to replace Interactive Intelligence in S&P 600 as of 12/5 close »

Genesys is acquiring…

NBHC

National Bank

$29.99

0.835 (2.86%)

ININ

Interactive Intelligence

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.55

0.46 (0.62%)

14:50
12/05/16
12/05
14:50
12/05/16
14:50
Hot Stocks
Belden CEO says targets long-term revenue growth 5%-7% »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

IMGN

ImmunoGen

$1.88

0.11 (6.21%)

14:49
12/05/16
12/05
14:49
12/05/16
14:49
Hot Stocks
Breaking Hot Stocks news story on ImmunoGen »

ImmunoGen to submit IND…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$26.29

-1.49 (-5.36%)

14:49
12/05/16
12/05
14:49
12/05/16
14:49
Options
Coupa Software options imply 19.3% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

IMGN

ImmunoGen

$1.88

0.11 (6.21%)

14:47
12/05/16
12/05
14:47
12/05/16
14:47
Hot Stocks
ImmunoGen reports preclinical data on IMGN632 presented at ASH meeting »

ImmunoGen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.